Navigation Links
Experimental drug shows promise in treating certain lymphomas
Date:4/16/2008

BIRMINGHAM, Ala. - New clinical data showed some cancer patients with recurrent lymphoma benefited from an experimental drug called AME-133v, said a researcher at the University of Alabama at Birmingham (UAB).

The data was presented April 15th during the 2008 annual meeting of the American Association for Cancer Research in San Diego.

Phase 1 clinical trial data showed AME-133v had a potent tumor-halting response in patients with a particular kind of cancer called follicular lymphoma, said Andres Forero, M.D., associate scientist at the UAB Comprehensive Cancer Center and lead presenter on the results.

"These first results suggest that AME-133v provides a mechanism of action that may be more potent and ultimately more effective than the treatments we have on hand," Forero said.

The testing was done in 22 patients treated at UAB and at other locations around the nation. Follicular lymphoma patients are being enrolled in a Phase 2 study.

About 22 percent of the lymphomas in the United States are of the follicular type, according to the American Cancer Society. The malignant cells tend to grow slowly in a circular pattern in the lymph nodes. Follicular lymphoma can be treated with chemotherapy, but the disease often returns after therapy is complete.

Research has shown that a new class of anticancer agents like AME-133v, a class called monoclonal antibodies, can lengthen survival times, Forero said.

In the UAB study, AME-133v was administered in combination with a standard chemotherapy agent sometime after the initial treatments had been given, and after the re-emergence of cancer.

The experimental drug triggered signaling pathways within cells that slow or stop lymphoma cancer's growth, and the drug combo was well-tolerated by the body and caused minimal side effects, Forero said.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Page: 1

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... Ogawa World USA ... its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D combines the ... each massage with a customized user profile and specialized massage program, each user has ...
(Date:5/3/2016)... NY (PRWEB) , ... May 03, 2016 , ... ... for the healthcare industry, announced today that Legacy Health is expanding its use ... Works platform), after a highly successful initial proof of concept. The Portland, Oregon ...
(Date:5/3/2016)... VA (PRWEB) , ... May 03, 2016 , ... ... provider of innovative information technology (IT) solutions and digital consulting services to the ... Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in support ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Huntington Beach ... type of surgical procedure that can be used to diagnose and treat joint problems. ... be inserted. These instruments include a special lighting system and lens that illuminate and ...
(Date:5/3/2016)... ... ... Branches, Inc. is proud to have been selected as a Macy’s grant ... Miami. Macy’s is a wonderful community partner and has helped to support Branches’ student ... and academic support to elementary students 5 days a week. Summer Shade, a 7 ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... FRANCISCO , May 2, 2016 ... expected to reach USD 11.1 billion by 2024, ... View Research, Inc. Major drivers of the sonography ... therapeutic areas and government recommendations for periodic ultrasound ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... 2016 ReportsnReports.com adds "Pulmonary ... research report that provides an overview of the ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Pulmonary ...
(Date:4/29/2016)... , April 29, 2016 ... Directeur Financier Sanofi, leader ... publie ses résultats pour le premier ... Groupe, Jérôme Contamine, commente les résultats ... les perspectives pour le reste de ...
Breaking Medicine Technology: